Regulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research note published on Saturday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Several other research analysts have also weighed in on the stock. Leerink Partners reiterated a “market perform” rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Leerink Partnrs cut shares of Regulus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 30th. Wells Fargo & Company reiterated an “equal weight” rating and set a $9.00 price objective on shares of Regulus Therapeutics in a report on Thursday, May 1st. Jones Trading restated a “hold” rating and issued a $7.00 target price (down previously from $8.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a research note on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $8.50.

Regulus Therapeutics Stock Up 0.3 %

Shares of Regulus Therapeutics stock opened at $7.87 on Friday. Regulus Therapeutics has a 12 month low of $0.83 and a 12 month high of $8.20. The stock has a market cap of $521.33 million, a PE ratio of -7.36 and a beta of 0.49. The business has a fifty day simple moving average of $2.76 and a 200-day simple moving average of $1.88.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.14. Analysts expect that Regulus Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Regulus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC bought a new position in Regulus Therapeutics during the 3rd quarter valued at about $46,000. Barclays PLC raised its stake in shares of Regulus Therapeutics by 285.2% in the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock valued at $132,000 after acquiring an additional 62,549 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Regulus Therapeutics by 193.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock worth $124,000 after acquiring an additional 52,059 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Regulus Therapeutics by 20.5% in the 4th quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company’s stock worth $185,000 after acquiring an additional 19,900 shares in the last quarter. Finally, PEAK6 LLC acquired a new stake in Regulus Therapeutics during the 4th quarter valued at $95,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.